We have found a hepatotrophic factor in plasma or sera of patients with fulminant hepatic failure and have purified human hepatocyte growth factor from plasma of these patients. In this study we developed an enzyme-linked immunosorbent assay with high specificity and sensitivity for human hepatocyte
Serum hepatocyte growth factor levels in liver diseases: Clinical implications
โ Scribed by Goshi Shiota; Jun-Ichi Okano; Hironaka Kawasaki; Tomokazu Kawamoto; Toshikazu Nakamura
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 793 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
Clinical Implications
GOSHI SHIOTA,' JUN-ICHI OKANO,' HIRONAKA KAWASAKI,' TOMOKAZU KAWAMOTO,' AND TOSHIKAZU NAKA1LIURA3
Although recent studies have shown that hepatocyte growth factor (HGF) is a potent mitogen in uiuo, the significance of serum HGF in liver diseases remains unclear. To clarify clinical significance of serum HGF in liver diseases, serum HGF was measured in 127 patients with liver diseases and in 200 healthy individuals, using a highly sensitive immunoradiometric assay (IRMA). This assay is specific for HGF and is sensitive enough to detect 0.1 ng/mL of HGF. Mean values for serum HGF in acute hepatitis (AH), chronic hepatitis (CH), liver cirrhosis (LC), hepatocellular carcinoma (HCC), primary biliary cirrhosis (PBC), fulminant hepatic failure (FHF'), and normal controls were 0.45,0.40,1.05,1.06,0.44,16.40, and 0.27 ng/mL, respectively. Serum HGF levels in these diseases were significantly increased compared with those in the controls (P < .001), and exhibited a positive correlation with total bilirubin, indocyanine green (ICG) test (R15), asparate aminotransferase (AST), and a negative correlation with albumin and prothrombin time (P < .001). Cirrhotic patients with modified Child class C had higher levels of serum HGF than those graded as modified Child class A or B (P < .001). In CH, serum HGF levels were significantly related to the histological activity index (HAI) score (P < .002). Seven patients with HCC who underwent transcatheter arterial embolization (TAE) exhibited a gradual increase in serum HGF levels up to day 4 after treatment; these higher levels were maintained until day 7, although AST reached a peak on day 2 and then decreased gradually. During clinical courses of patients with AH and CH, serum HGF
๐ SIMILAR VOLUMES
Serum human hepatocyte growth factor levels were measured using a newly developed enzyme-linked immunosorbent assay kit in patients with liver diseases. Serum human hepatocyte growth factor levels were increased in correlation with derangements of prothrombin time, total bilirubin and other paramete
After a partial hepatectomy, TGF-a mRNA has been shown of chronic liver disease; CH, chronic hepatitis; LC, liver cirrhosis; LI, labeling index; RTto increase in hepatocytes at the time of DNA synthesis con-PCR, reverse-transcriptase polymerase chain reaction; cDNA, complementary DNA.
Transforming growth factor a (TGFa) is supposed to chain polypeptide of 50 amino acids that is expressed in act as a mitogen for hepatocytes in an autocrine manner cultured hepatocytes and secreted into culture medium in vitro and in vivo. Retarded liver regeneration is a after stimulation with mito
## Abstract Hepatocyte growth factor (HGF) has been shown to be involved in angiogenesis, epithelial cell proliferation, and osteoclast activation. HGF and its receptor are expressed on myeloma cell lines and could be involved in the pathogenesis of bone destruction in multiple myeloma (MM). The ai